GLOBAL LEADERS : looking now at the bigger picture

Editorial :

The issue of the optimal antithrombotic therapy following a percutaneous coronary intervention (PCI) or an acute coronary syndrome has remained a question in modern cardiology, despite many successive breakthroughs. Nearly two decades ago, the Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) trial demonstrated the superiority of dual antiplatelet therapy, based on aspirin with a P2Y12 inhibitor over aspirin and placebo, in this high-risk population1. Since then, numerous trials have evaluated various strategies of more or less prolonged DAPT duration with more or less potent P2Y12 inhibitors in association with aspirin. […]